Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 202

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Type 2 Diabetes Mellitus: Update on Diagnosis, Pathophysiology, and Treatment

Mahler, R. J.·1999·Journal of Clinical Endocrinology & Metabolism

Abstract

SIXTEEN million individuals in the United States with type 2 diabetes mellitus and an additional 30–40 million with impaired glucose tolerance result in health care costs exceeding 100 billion dollars annually (1). Treatment is predominantly directed at microvascular and macrovascular complications (2). In type 1 diabetes mellitus the relationship between glycemic control and microvascular complications has been well established (3). The relationship between tight glycemic control and microvascular disease in type 2 diabetes mellitus appears to be established in the recently completed United Kingdom prospective diabetes study (4, 5). Despite the morbidity and mortality associated with retinopathy, nephropathy, and neuropathy, cardiovascular disease remains the leading cause of death in type 2 diabetes mellitus (6, 7). Consequently, the treatment of confounding risk factors of obesity, hypertension, and hyperlipidemia assumes major importance and must be coordinated with good glycemic control for reduction in total mortality in type 2 diabetes mellitus (6–11). Based on the emerging relationship between the degree of glycemic control and microvascular complications as well as the contribution of hyperglycemia in the development of macrovascular disease, it is the purpose of this review to summarize the current state of knowledge to provide a rational basis for the treatment of type 2 diabetes mellitus. The definition of type 2 diabetes mellitus, previously termed noninsulin-dependent diabetes mellitus, was recently modified by the American Diabetes Association. Several criteria may be used independently to establish the diagnosis: 1) a 75-g oral glucose tolerance test with a 2-h value of 200 mg/dL or more, 2) a random plasma glucose of 200 mg/dL or more with typical symptoms of diabetes, or 3) a fasting plasma glucose of 126 mg/dL or more on more than one occasion (7). Fasting glucose values are preferred for their convenience, reproducibility, and correlation with increased risk of microvascular complications. The term impaired fasting glucose has been defined as fasting plasma glucose of 110 or more and 125 mg/dL or less (7). Impaired glucose tolerance (IGT) is defined as a 2-h plasma glucose value of 140 or more and of less than 200 mg/dL during an oral glucose tolerance (12). Individuals with impaired fasting glucose and IGT are considered to be at high risk for the development of diabetes and macrovascular disease (13, 14). Although one third of these patients will eventually develop diabetes, dietary modification and exercise can lower the risk of progression from impaired glucose tolerance to type 2 diabetes; and may also prevent the development of IGT in nondiabetic individuals at high risk (14). Pharmacological agents may also be of benefit in limiting the progression from IGT to diabetes (13, 15). Type 2 diabetes mellitus is a heterogeneous disorder with varying prevalence among different ethnic groups. In the United States the populations most affected are native Americans, particularly in the desert Southwest, Hispanic-Americans, and Asian-Americans (1). The pathophysiology of type 2 diabetes mellitus is characterized by peripheral insulin resistance, impaired regulation of hepatic glucose production, and declining β-cell function, eventually leading toβ -cell failure. The primary events are believed to be an initial deficit in insulin secretion and, in many patients, relative insulin deficiency in association with peripheral insulin resistance (16, 17). β-Cell dysfunction is initially characterized by an impairment in the first phase of insulin secretion during glucose stimulation and may antedate the onset of glucose intolerance in type 2 diabetes (18). Initiation of the insulin response depends upon the transmembranous transport of glucose and coupling of glucose to the glucose sensor. The glucose/glucose sensor complex then induces an increase in glucokinase by stabilizing the protein and impairing its degradation. The induction of glucokinase serves as the first step in linking intermediary metabolism with the insulin secretory apparatus. Glucose transport inβ -cells of type 2 diabetes patients appears to be greatly reduced, thus shifting the control point for insulin secretion from glucokinase to the glucose transport system (19, 20). This defect is improved by the sulfonylureas (21, 22). Later in the course of the disease, the second phase release of newly synthesized insulin is impaired, an effect that can be reversed, in part at least in some patients, by restoring strict control of glycemia. This secondary phenomenon, termed desensitization or β-cell glucotoxicity, is the result of a paradoxical inhibitory effect of glucose upon insulin release and may be attributable to the accumulation of glycogen within the β-cell as a result of sustained hyperglycemia (23). Other candidates that have been proposed are sorbital accumulation in the β-cell or the nonenzymatic glycation ofβ -cell protein

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.84.4.1165

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 202

Metadata

Authors
Mahler, R. J.
Venue
Journal of Clinical Endocrinology & Metabolism
Published
1999-04-01
Volume
84
Issue
4
Pages
1165-1171
ISSN
0021-972X (ISSN-L)
OpenAlex
W2099419173
Cited by
202
References
14
FWCI
3.83
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Type 2 Diabetes Mellitus: Update on Diagnosis, Pathophysiology, and Treatment. https://app.cochat.ai/papers/10.1210/jc.84.4.1165
The paper
Mahler, R. J. (1999). Type 2 Diabetes Mellitus: Update on Diagnosis, Pathophysiology, and Treatment. Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.84.4.1165

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.